Innovative Biologics, Inc Names Jeff Conroy to Board of Directors

Manassas, VA. Innovative Biologics, Inc. has named Jeff Conroy as a director of the corporation. Mr. Conroy is the CEO of Adjuvant, Inc, a life science transaction advisory firm and the Managing Director of Windward Investments, LLC.

“As we look to extend our anti-infective small molecule programs, we wanted to leverage Jeff’s transaction expertise to advance our partnering initiatives”, said C.W. Gilluly, President of Innovative Biologics, Inc.

“Innovative Biologics has a proven technology platform, based upon the use of cyclodextrins as anti-infectives”, said Jeff Conroy, “and I look forward to helping the company extend their success in biodefense, MRSA, pseudomonas and HCV.”

Innovative Biologics, Inc. (http://www.innovbio.com ) is focused on the discovery of new drugs targeting anthrax and other microbes producing pore-forming toxins. Many pathogens utilize the formation of pores in the membranes of target cells in the process of infection. IBI has developed a platform to identify compounds which inhibit their action, based on blocking of the target pore with molecules having the same symmetry as the pore itself, using ß-cyclodextrin as a scaffold. Beyond our programs related to Biodefense, our approach has wider application across infectious disease.

Adjuvant, Inc. is a transaction advisory firm focused on developing strategic alliances in the life science market. The Adjuvant BIOdB (ww.biodb.com) is our global database of the alliance and licensing priorities of over 2,500 biotechnology and pharmaceutical companies. Please contact Chris Robson at 703.266.2740 x114.